Regeneron Pharmaceuticals (NASDAQ:REGN) dropped 1.6% after the company's loss against Amgen (NASDAQ:AMGN) in a patent case over Regeneron's blockbuster Eylea drug was affirmed by an appeals court.

Regeneron's oncology platform is poised to be a significant growth driver in the next decade. Read why REGN stock remains a ...

Finally, TD Cowen dropped their price objective on shares ... Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last announced its earnings results on Tuesday, February 4th.

View our complete analysis and fair value estimate and you decide. NasdaqGS:REGN Revenue & Expenses Breakdown as at Apr 2025 Uncover 10 companies that survived and thrived after COVID and have the ...